Skip to content
Publicly Available Published by De Gruyter August 25, 2011

Intracranial hypertension in pediatric patients treated with recombinant human growth hormone: data from 25 years of the Genentech National Cooperative Growth Study

  • Richard Noto , Thomas Maneatis , James Frane , Kimberly Alexander , Barbara Lippe and D. Aaron Davis EMAIL logo

Abstract

Intracranial hypertension (IH) is a rare condition in children. However, a relationship between recombinant human growth hormone (rhGH) therapy and IH has been well documented. Risk factors were assessed for 70 rhGH-naive patients enrolled in the National Cooperative Growth Study with reports of IH after treatment initiation. Patients with severe growth hormone deficiency, Turner syndrome, chronic renal insufficiency (CRI), and obesity (particularly in the CRI group) were at highest risk of developing IH during the first year of therapy, suggesting initiation of careful early monitoring. In some patients, factors such as corticosteroid use or other chromosomal abnormalities appear to confer a delayed risk of IH, and these patients should be monitored long-term for signs and symptoms of IH.


Corresponding author: D. Aaron Davis, MD, Genentech, Inc., 1 DNA Way, 26-3150 MS#58b, South San Francisco, CA 94080, USA Phone: +1 650 4676207, Fax: +1 866 5209951

Received: 2011-6-21
Accepted: 2011-7-2
Published Online: 2011-08-25
Published in Print: 2011-10-1

©2011 by Walter de Gruyter Berlin Boston

Downloaded on 30.4.2024 from https://www.degruyter.com/document/doi/10.1515/JPEM.2011.319/html
Scroll to top button